Spectrum Vascular

Spectrum Vascular is a medical device company established in 2023, with a specific focus on developing and manufacturing solutions for vascular access and medication management. The company was strategically formed through the acquisition of the vascular access business units from two established players in the medical technology field: Cook Medical in 2023 and AngioDynamics in 2024. This formation strategy allowed Spectrum Vascular to immediately possess a robust portfolio of market-tested products.

The company's business model is centered on supplying high-quality medical devices directly to healthcare providers, including hospitals and clinics. In a significant operational milestone, Spectrum Vascular transitioned all of its 'Order to Cash' operations in-house in 2024, aiming to provide streamlined customer service, product fulfillment, and direct clinical support to its clients. The company's financial structure was significantly bolstered in March 2025 through a strategic investment and recapitalization led by SK Capital Partners, a private investment firm with expertise in the life sciences sector. Event Capital Strategies (ECS), the company's initial majority investor, retained a significant ownership stake, ensuring strategic continuity.

Spectrum Vascular's product lines are designed to address common and costly complications in vascular care, primarily focusing on reducing healthcare-acquired infections and thrombus-related issues. The core of its offering includes the SV Spectrum™ and SV BioFlo™ technology platforms. The SV Spectrum™ catheters are impregnated with the antibiotics minocycline and rifampin to provide protection against central line-associated bloodstream infections (CLABSIs). The SV BioFlo™ catheters utilize Endexo® technology, a surface-modifying macromolecule that reduces the accumulation of thrombus, a common cause of catheter occlusion. The portfolio includes a comprehensive range of peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and Midline products, many of which were part of the acquisitions from Cook Medical and AngioDynamics. In January 2025, the company further expanded its offerings by becoming the exclusive distributor for Piccolo Medical's catheter navigation devices, including the ECGuide™ and SmartPICC® product lines.

In April 2025, the company appointed a new executive team to guide its next phase of growth. Ken Miller, a veteran with over 35 years of experience in the medical device industry at companies like Koru Medical Systems, BD, and Novo Nordisk, was named Chief Executive Officer. Doug Shook, with over two decades of commercial leadership experience at ICU Medical and Smiths Medical, joined as Chief Commercial Officer. The board also includes experienced individuals such as Raymond W. Cohen, a seasoned medical technology executive who serves as an independent director.

Keywords: vascular access devices, medication management, medical device manufacturing, central venous catheters, CVC, peripherally inserted central catheters, PICC, thrombus reduction, antimicrobial catheters, CLABSI prevention, catheter-related bloodstream infection, Endexo technology, SV BioFlo, SV Spectrum, Cook Medical acquisition, AngioDynamics acquisition, SK Capital Partners, Event Capital Strategies, medical technology, healthcare-acquired infections, catheter tip confirmation, direct medical supplier, Ken Miller, Doug Shook, Raymond W. Cohen